TMO · XBRL financial data

Thermo Fisher Scientific financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TMO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	32,218	39,211	44,915	42,857	42,879	44,556
Research and development	1,181	1,406	1,471	1,337	1,390	1,397
Selling, general and administrative	6,930	8,007	8,993	8,445	8,595	8,732
Operating income (loss)	7,794	10,028	8,393	6,859	7,337	7,746
Interest income	65	43	272	879	1,078	993
Interest expense	553	536	726	1,375	1,390	1,419
Other income (expense)	(81)	(694)	(104)	(65)	12	(12)
Income tax expense (benefit)	850	1,109	703	284	657	547
Net income (loss)	—	—	—	5,995	6,335	6,704
Earnings per share, basic USD per share	16.09	19.62	17.75	15.52	16.58	17.77
Earnings per share, diluted USD per share	15.96	19.46	17.63	15.45	16.53	17.74
Weighted average shares, basic millions of shares	396	394	392	386	382	377
Weighted average shares, diluted millions of shares	399	397	394	388	383	378

Fiscal years (TMO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	10,325	4,477	8,524	8,077	4,009	9,852
Short-term investments	—	—	—	3	1,561	253
Accounts receivable	5,741	7,977	8,115	8,221	8,191	8,900
Inventory	4,029	5,051	5,634	5,088	4,978	5,425
Total current assets	21,957	20,113	25,229	24,589	22,137	28,707
Property and equipment, net	5,912	8,333	9,280	9,448	9,306	10,565
Right-of-use asset	775	1,531	1,593	1,556	1,489	1,447
Goodwill	26,041	41,924	41,196	44,020	45,853	49,362
Total assets	69,052	95,123	97,154	98,726	97,321	110,343
Accounts payable	2,175	2,867	3,381	2,872	3,079	3,622
Total current liabilities	10,304	13,436	17,010	14,012	13,332	15,189
Long-term debt	19,107	—	—	—	—	—
Lease liability, non-current	626	1,203	1,313	1,244	1,239	1,195
Retained earnings	28,116	35,431	41,910	47,364	53,102	59,156
Total stockholders' equity	34,507	40,793	43,978	46,735	49,584	53,407
Total liabilities and equity	69,052	95,123	97,154	98,726	97,321	110,343
Common shares outstanding (cover page) millions of shares	394	391	385	381	377	371

Fiscal years (TMO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	—	—	5,995	6,335	6,704
Stock-based compensation	196	230	307	278	301	310
Net cash from operating activities	8,289	9,312	9,154	8,406	8,667	7,818
Purchases of property and equipment	1,474	2,523	2,243	1,479	1,400	1,525
Net cash from investing activities	(1,510)	(21,932)	(2,159)	(5,142)	(5,841)	(4,047)
Share repurchases	1,500	2,000	3,000	3,000	4,000	3,000
Dividends paid	337	395	455	523	583	636
Proceeds from long-term debt	3,464	18,137	3,193	5,942	1,204	7,759
Repayments of long-term debt	713	11,738	375	5,782	3,607	2,412
Net cash from financing activities	959	6,581	(2,810)	(3,622)	(6,792)	1,801
Net change in cash	7,914	(5,845)	4,046	(440)	(4,057)	5,839

SIC 3829 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3829 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Thermo Fisher Scientific	5,461	12,137	2,550*	370.5M	Q3 FY26 10-QSep 26, 2026
KLA	1,532	4,136	1,531	1.3B	Q1 FY27 10-QSep 30, 2026
Danaher	5,682	6,554	1,886*	703.5M	Q3 FY26 10-QSep 25, 2026
Trane Technologies	not reported	6,760	1,313*	218.9M	Q3 FY26 10-QSep 30, 2026
Roper Technologies	311	2,172	821*	99.0M	Q3 FY26 10-QSep 30, 2026
Ametek	666	2,220	561*	229.3M	Q3 FY26 10-QSep 30, 2026
Coherent	1,162	2,046*	69*	195.8M	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.